Predictive Oncology Inc. Prices $344.4 Million in Private Placements to Fund Digital Asset Treasury Strategy

Predictive Oncology Inc. (NASDAQ: POAI) has announced the pricing of two concurrent private placement transactions totaling approximately $344.4 million to support its new digital asset treasury strategy. The financing includes a $51.7 million cash private investment in public equity (PIPE) and a $292.7 million crypto PIPE involving pre-funded warrants, with proceeds designated for ATH acquisition, working capital, and general corporate purposes.

The company will initiate a digital asset treasury strategy centered on accumulating ATH, the native utility token of the Aethir ecosystem. This strategic move represents a significant diversification for the biotechnology company, which has traditionally focused on cancer research and drug discovery. The substantial funding indicates strong investor confidence in both the company's core operations and its new digital asset direction.

While pursuing this new digital asset strategy, Predictive Oncology continues to operate its scientifically validated AI platform, PEDAL, which can predict with 92% accuracy whether a tumor sample will respond to a specific drug compound. This technology allows for more informed selection of drug and tumor type combinations for subsequent in-vitro testing. The company maintains its position at the forefront of artificial intelligence and machine learning applications in early drug discovery and development for cancer patients worldwide.

The company's extensive biobank of more than 150,000 assay-capable heterogenous human tumor samples, combined with its AI platform, provides academic and industry partners with one of the industry's broadest AI-based drug discovery solutions. This comprehensive approach is further enhanced by the company's wholly owned CLIA laboratory facility. For more information about the company's operations, visit https://predictive-oncology.com/.

The announcement was distributed through CryptoCurrencyWire (CCW), a specialized communications platform focusing on blockchain and cryptocurrency sectors. CCW operates as part of the Dynamic Brand Portfolio at IBN, providing comprehensive distribution services including wire solutions, article syndication to over 5,000 outlets, press release enhancement, and social media distribution. Additional details about the distribution platform can be found at https://www.CryptoCurrencyWire.com.

This substantial funding round and strategic pivot toward digital assets could signal broader trends in biotechnology companies exploring alternative treasury management strategies. The move may influence how other healthcare and technology firms approach asset diversification while maintaining their core research and development operations. The combination of traditional biotechnology with emerging digital asset strategies represents an innovative approach to corporate finance in the evolving healthcare technology landscape.